Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nucleoside diphosphate kinase 7 (NME7) is a member of the nucleoside diphosphate kinase enzyme family, responsible for catalyzing the reversible transfer of phosphate groups from nucleoside triphosphates to nucleoside diphosphates, thereby maintaining cellular pools of NTPs essential for nucleic acid synthesis and other processes[2][4][5]. NME7 also functions as a regulatory protein in the gamma-tubulin ring complex, modulating microtubule nucleation critical for cytoskeletal organization and cell division[7]. Additionally, this isoform has unique 3'-5' exonuclease activity with specificity for single-stranded DNA, suggesting possible roles in DNA repair mechanisms[6]. Although its enzymatic function is well established, the precise physiological and pathological roles of NME7 in human disease remain under investigation, and as of now, it is not directly targeted by approved therapeutic agents.
Most drugs would act by inhibition of kinase activity (blocking phosphate group transfer); some might exploit its exonuclease function
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleoside diphosphate kinase 7 (NME7).